3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
26
Thoracic
2
Head & Neck
2
Genitourinary
2
Breast
2
Other hematologic neoplasm
1
Lymphoid
1
Gynecologic
1
Dermatologic
1
CNS
1
Conditions
Ovarian Neoplasms
106
Fallopian Tube Neoplasms
48
Carcinoma, Ovarian Epithelial
31
Uterine Cervical Neoplasms
28
Pancreatic Neoplasms
13
Endometrial Neoplasms
13
Neoplasms
10
Colorectal Neoplasms
10
Carcinoma, Non-Small-Cell Lung
10
Breast Neoplasms
10
Recurrence
7
Prostatic Neoplasms
7
Neoplasm Metastasis
7
Lung Neoplasms
7
Triple Negative Breast Neoplasms
6
Stomach Neoplasms
6
Sarcoma
6
Urinary Bladder Neoplasms
5
Squamous Cell Carcinoma of Head and Neck
5
Peritoneal Neoplasms
5
Cholangiocarcinoma
5
Small Cell Lung Carcinoma
4
Melanoma
4
Head and Neck Neoplasms
4
Esophageal Neoplasms
4
Colonic Neoplasms
4
Vulvar Neoplasms
3
Uterine Neoplasms
3
Multiple Myeloma
3
Carcinoma
3
Interventions
pembrolizumab
20
Nivolumab
10
Cyclophosphamide
10
atezolizumab
6
Specimen Handling
6
fludarabine
5
Magnetic Resonance Spectroscopy
5
cabozantinib
4
Ipilimumab
4
Bevacizumab
4
lenvatinib
3
X-Rays
3
Trastuzumab
3
Paclitaxel
3
Oxaliplatin
3
Immunoglobulin G
3
Fluorodeoxyglucose F18
3
ulixertinib
2
sargramostim
2
poly ICLC
2
epacadostat
2
enzalutamide
2
durvalumab
2
cemiplimab
2
budigalimab
2
avelumab
2
aldesleukin
2
aflibercept
2
Sirolimus
2
Psychiatric Rehabilitation
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Carcinoma, Hepatocellular
×
Gemcitabine
×
Gynecologic
×
Clear all
NCT05007106
2025-08-14
KEYVIBE-005
Merck Sharp & Dohme LLC
Phase 2
Completed
613 enrolled